prof. Filip Van den Bosch
- Work address
-
C. Heymanslaan 10, ingang 12 - verdieping 6
9000 Gent - Filip.VanDenBosch@UGent.be
- ORCID iD
-
0000-0002-3561-5932
Show
Sort by
-
Improving the design of RCTs in non-radiographic axial spondyloarthritis
-
- Journal Article
- open access
Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial
-
Response to : 'Correspondence on 'Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis : results of the open-label, pragmatic, cluster-randomised TICOSPA trial'' by Cai and Peng response
-
Peripheral manifestations are major determinants of disease phenotype and outcome in new onset spondyloarthritis
(2022) RHEUMATOLOGY. -
Cluster analysis in early axial spondyloarthritis predicts poor outcome in the presence of peripheral articular manifestations
(2022) RHEUMATOLOGY. -
Development of an environmental contextual factor item set relevant to global functioning and health in patients with axial spondyloarthritis
-
- Journal Article
- A1
- open access
Safety and efficacy of upadacitinib in patients with active ankylosing spondylitis and an inadequate response to nonsteroidal antiinflammatory drug therapy : one-year results of a double-blind, placebo-controlled study and open-label extension
-
- Journal Article
- A1
- open access
Real-world efficacy and safety of apremilast in Belgian patients with psoriatic arthritis : results from the prospective observational APOLO study
-
- Journal Article
- A1
- open access
Efficacy and safety of risankizumab for active psoriatic arthritis : 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial
-
Response to : ‘Finding the right one’ by Zanwar